Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:KRYS NASDAQ:NUVL NASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$8.91$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsKRYSKrystal Biotech$317.97$288.44$127.99▼$331.49$9.37B0.53235,850 shs291,320 shsNUVLNuvalent$123.25$104.21$71.13▼$123.62$9.74B1.154.31 million shs7.24 million shsRGCRegencell Bioscience$18.83$26.77$9.39▼$83.60$9.31B1.6687,625 shs85,067 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf0.00%0.00%-64.46%-47.25%+53.59%KRYSKrystal Biotech0.00%+5.64%+3.81%+27.11%+131.98%NUVLNuvalent0.00%+35.51%+20.48%+23.83%+57.53%RGCRegencell Bioscience0.00%-5.80%-34.11%-16.98%+1,882,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$3.64$8.91$0.72▼$5.05$2.54B1.531.24 million shs1.32 million shsKRYSKrystal Biotech$317.97$288.44$127.99▼$331.49$9.37B0.53235,850 shs291,320 shsNUVLNuvalent$123.25$104.21$71.13▼$123.62$9.74B1.154.31 million shs7.24 million shsRGCRegencell Bioscience$18.83$26.77$9.39▼$83.60$9.31B1.6687,625 shs85,067 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf0.00%0.00%-64.46%-47.25%+53.59%KRYSKrystal Biotech0.00%+5.64%+3.81%+27.11%+131.98%NUVLNuvalent0.00%+35.51%+20.48%+23.83%+57.53%RGCRegencell Bioscience0.00%-5.80%-34.11%-16.98%+1,882,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 3.25BuyN/AN/AKRYSKrystal Biotech 2.83Moderate Buy$324.111.93% UpsideNUVLNuvalent 2.20Hold$131.156.41% UpsideRGCRegencell Bioscience 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CURLF, RGC, NUVL, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$140.00 ➝ $124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.006/9/2026NUVLNuvalent BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$152.00 ➝ $124.006/9/2026NUVLNuvalent Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$122.856/9/2026NUVLNuvalent Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$124.006/9/2026NUVLNuvalent Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/3/2026CURLFCuraleaf Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.27B2.01$0.05 per share66.42$1.11 per share3.28KRYSKrystal Biotech$389.13M24.09$7.29 per share43.62$42.06 per share7.56NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ARGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$231.07M-$0.13N/AN/AN/A-7.76%-8.11%-2.36%N/AKRYSKrystal Biotech$204.83M$7.4842.5130.23N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ALatest CURLF, RGC, NUVL, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026RGCRegencell BioscienceN/A-$0.0050N/A-$0.0050N/AN/A5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026CURLFCuraleaf-$0.24$0.27+$0.51$0.09$316.62 million$324.23 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.051.560.74KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14RGCRegencell BioscienceN/A1.41N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%RGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipCURLFCuraleafN/AKRYSKrystal Biotech13.10%NUVLNuvalent5.02%RGCRegencell BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,554698.73 millionN/ANot OptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/ACURLF, RGC, NUVL, and KRYS HeadlinesRecent News About These CompaniesREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 14 at 6:17 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 14 at 12:00 PM | globenewswire.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13 at 11:31 AM | markets.businessinsider.comREGENCELL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 13 at 9:19 AM | newsfilecorp.comNRGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 13 at 8:20 AM | globenewswire.comRGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitJune 12 at 5:51 PM | prnewswire.comRegencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 12 at 3:54 PM | prnewswire.comBragar Eagel & Squire, P.C. Reminds Regencell Bioscience Holdings Limited (NASDAQ:RGC) Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff RoleJune 12 at 12:35 PM | globenewswire.comREGENCELL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100Kto Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGCJune 12 at 12:26 PM | globenewswire.comRGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Limited Securities Lawsuit - Contact The Gross Law FirmJune 12 at 11:46 AM | globenewswire.comREGENCELL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 11, 2026 | newsfilecorp.comNRGC SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026June 11, 2026 | newsfilecorp.comNDeadline Alert: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitJune 11, 2026 | globenewswire.comLost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallStJune 11, 2026 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGCJune 11, 2026 | prnewswire.comREGENCELL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important June 23 Deadline in Securities Class Action - RGCJune 10, 2026 | newsfilecorp.comNDEADLINE ALERT for RGC, SES, FSK, GPK: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsJune 10, 2026 | globenewswire.comDEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 10, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor HarmJune 10, 2026 | globenewswire.comRGC INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026June 10, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026CURLF, RGC, NUVL, and KRYS Company DescriptionsCuraleaf OTCMKTS:CURLF$3.64 0.00 (0.00%) As of 06/4/2026Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Krystal Biotech NASDAQ:KRYS$317.97 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$318.50 +0.53 (+0.17%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$123.25 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$123.25 +0.00 (+0.00%) As of 06/12/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Regencell Bioscience NASDAQ:RGC$18.83 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$19.70 +0.87 (+4.62%) As of 06/12/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
